ALKS

Rating neutralAI Memo

Alkermes

As of 2026-09-26/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-26 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Alixorexton idiopathic-hypersomnia Phase 2 readout • 2026-12-31

Base target: $43 / p=50% prob

Biggest risk

The ALKS 7290 announcement did not establish placebo-adjusted efficacy, while higher R&D and SG&A spending and a lowered GAAP outlook constrain near-term earnings quality. Post-announcement analyst interpretations differ: RBC retained a $56 target, while the supplied analyst roundup reports a reiterated $38 Bank of America target and an inconclusive-data view analyst roundup.

Invalidation

Break below $31 or thesis failure.

What would change my mind?

Q2 revenue of $496 million exceeded the $454 million consensus cited by a stored Zacks review, and established products plus LUMRYZ provide funding for the orexin pipeline [#SEC-8K-2026-07-28]. Positive alixorexton data and eventually convincing placebo-controlled ADHD data could support a rerating.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-26

Base target

$43

p=50%

Bull target

$54

p=25%

Bear target

$31

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Commercial sales and expense execution against 2026 guidance
Placebo-controlled ALKS 7290 ADHD Phase 2 data
Q2 revenue of $496 million exceeded the $454 million consensus cited by a stored Zacks review, and established products plus LUMRYZ provide funding for the orexin pipeline [#SEC-8K-2026-07-28].

BearKey bullets

ALKS 7290 Phase 1b symptom changes were exploratory, measured over 14 days, and disclosed without a treatment-versus-placebo efficacy result; Phase 2 could fail to replicate them [#8-K-2026-09-21].
Alixorexton's upcoming idiopathic-hypersomnia readout could disappoint or be delayed [#SEC-8K-2026-07-28].
Commercial growth may be less durable than the Q2 headline suggests: the company identified approximately $7 million of LUMRYZ shipment-timing benefit and approximately $4 million of ARISTADA gross-to-net favorability SEC-filed earnings release.

WatchKey bullets

Alixorexton idiopathic-hypersomnia Phase 2 readout

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $43 (p=50%)

Target spread vs base: +26% / -28%

Scenario probabilities

Bull Target: $54 (p=25%)Base Target: $43 (p=50%)Bear Target: $31 (p=25%)

Commentary

The Phase 1b release was favorable in company framing, but the market did not sustain an advance: ALKS closed up 1.82% on September 21, then fell from $44.18 to the $40.85 September 25 anchor, a decline of about 7.5% historical closes. That sequence is not proof of a single cause. Analyst views are mixed rather than uniformly revised upward. Social coverage is absent; the zero-valued social, options, short-interest, and employee fields are missing-data placeholders, not neutral measurements.

As of 2026-09-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Commercial sales and expense execution against 2026 guidance
Placebo-controlled ALKS 7290 ADHD Phase 2 data

Scenarios

Bull Target (Scenario probability)

$54 / p=25% prob

Base Target (Scenario probability)

$43 / p=50% prob

Bear Target (Scenario probability)

$31 / p=25% prob

Analysis 2026-09-26 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Alixorexton idiopathic-hypersomnia Phase 2 readout
Management expects topline results toward year-end 2026. A convincing placebo-controlled result could broaden the orexin portfolio opportunity; an equivocal result would weaken it [#SEC-8K-2026-07-28].
Prob 65.00% • Move 12.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Commercial sales and expense execution against 2026 guidance
2026-12-31
Q2 proprietary-product sales were $411.7 million, but R&D and SG&A rose year over year. Alkermes retained its $1.73–$1.84 billion revenue and $370–$410 million adjusted-EBITDA ranges while lowering its GAAP earnings outlook. Delivery across LUMRYZ and the established portfolio, without further expense pressure, is the near-term test [#SEC-8K-2026-07-28].
Prob 60% • Move 5% • Priced-in 65%

Long-term Catalysts

Months to a year

Placebo-controlled ALKS 7290 ADHD Phase 2 data
2027-12-31
The September 21 Phase 1b announcement reported dose-dependent improvements from baseline, but those endpoints were exploratory and the study was not powered to establish a treatment-placebo difference [#8-K-2026-09-21]. The enrolling Phase 2 trial is expected to produce data in 2027 and is the more decisive efficacy test SEC-filed company release.
Prob 55% • Move 15% • Priced-in 40%

Risks

ALKS 7290 Phase 1b symptom changes were exploratory, measured over 14 days, and disclosed without a treatment-versus-placebo efficacy result; Phase 2 could fail to replicate them [#8-K-2026-09-21].
Alixorexton's upcoming idiopathic-hypersomnia readout could disappoint or be delayed [#SEC-8K-2026-07-28].
Commercial growth may be less durable than the Q2 headline suggests: the company identified approximately $7 million of LUMRYZ shipment-timing benefit and approximately $4 million of ARISTADA gross-to-net favorability SEC-filed earnings release.
Q2 R&D expense rose to $112.9 million from $77.4 million and SG&A to $217.6 million from $170.8 million; the company lowered its 2026 GAAP net-income outlook to a $95–$115 million loss while retaining adjusted-EBITDA guidance [#SEC-8K-2026-07-28].

Peers

Symbol	Summary
IONS	A similarly sized commercial-stage biopharma with a neurology pipeline, but different indications and drug technology; useful for development-risk context rather than a direct product multiple. Ionis company release
JAZZ	The closest indication-level comparison: Jazz markets XYWAV in narcolepsy and idiopathic hypersomnia. Its broader portfolio and different product economics limit direct valuation comparability. Jazz company release

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-26

Loading AI feed…

Symbol

Summary

IONS

A similarly sized commercial-stage biopharma with a neurology pipeline, but different indications and drug technology; useful for development-risk context rather than a direct product multiple. Ionis company release

JAZZ

The closest indication-level comparison: Jazz markets XYWAV in narcolepsy and idiopathic hypersomnia. Its broader portfolio and different product economics limit direct valuation comparability. Jazz company release